Publication on Zenagamtide Phase 2 Trial in Type 2 Diabetes Released

On August 15, 2026, a new publication was listed in The Lancet detailing a phase 2 clinical trial. The publication is titled "Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial." The trial evaluated zenagamtide, described as a unimolecular GLP-1 and amylin receptor agonist, administered orally once daily. It was conducted as a multicentre, randomised, parallel-group, double-blind, placebo-controlled, dose-finding study in adults with type 2 diabetes. The study falls under phase 2 of clinical development. This entry notes the appearance of the publication itself rather than any specific results, as no outcome data were provided beyond the trial description. The listing is indexed under PubMed ID 42532079. Readers interested in the broader research context around this compound, which remains categorized as unapproved and in the research stage, can consult the compound overview for additional background. No dosing, efficacy, or safety conclusions are reported here beyond the fact that this publication has been released in The Lancet.